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EFFECTS OF TAMOXIFEN ON PROSTAGLANDIN E2 INDUCED 
INSULIN-LIKE GROWTH FACTOR I EXPRESSION 
IN FETAL RAT OSTEOBLASTS 
Kristina A. Crothers and Thomas L. McCarthy. Section of Plastic and Reconstructive 
Surgery, Department of Surgery, Yale University, School of Medicine, New Haven, CT. 
ABSTRACT 
Despite its use as an antiestrogen in the treatment of breast cancer, tamoxifen also 
functions as a partial estrogen agonist, protecting against postmenopausal bone loss in 
these patients unable to receive estrogen replacement therapy. Among the many 
cytokines and growth factors under investigation, insulin-like growth factor I (IGF-I) has 
been one of those implicated as playing a role in the pathogenesis of postmenopausal 
osteoporosis. IGF-I gene expression is stimulated by agents such as prostaglandin E2 
(PGE2) that increase intracellular cyclic adenosine monophosphate (cAMP) via a protein 
kinase A (PKA) dependent mechanism. Treatment of primary cultures of fetal rat 
osteoblasts with 17p-estradiol suppresses the PGE2 dependent stimulation of IGF-I, 
suggesting a role for estrogen in maintaining a basal level of bone turnover Through 
preparation of cell cultures transiently transfected with estrogen receptor (ER) and the 
luciferase reporter plasmid controlled by promoter 1 of the IGF-I gene (IGF-I PI), we 
demonstrate that tamoxifen, though less potently than estrogen, also decreases PGE2 
stimulated IGF-I promoter activity. Like estrogen, tamoxifen treatment alone does not 
influence IGF-I expression. Tamoxifen treatment was not cytotoxic to cells, as equal 
concentrations weakly stimulated luciferase reporter expression under the control of a 
typical estrogen response element (ERE). Nuclear extracts from tamoxifen treated cells 
were prepared and used in gel mobility shift assays with DNA containing the atypical 
cAMP response element (CRE) in the IGF-I promoter required for PGE2 activation. As 

with estradiol, tamoxifen decreased the PGE2 induced bands detected by gel-mobility 
shift assay Thus tamoxifen appears to function similarly to estrogen in suppressing IGF- 
I in the absence of a typical estrogen response element within the IGF-I PI. These 
findings provide further evidence for an ERE-independent pathway of estrogen action, 
and help to elucidate the mechanism of the estrogen agonist effect of tamoxifen on bone. 
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Osteoporosis is a disease characterized by increased bone fragility and fracture 
risk resulting from a state of low bone mass and deterioration of the microstructure of 
bone (Johnston and Slemenda, 1995). Peak adult bone mass is attained usually in the 
third decade, with all individuals undergoing subsequent age-related bone loss. The 
incidence of osteoporotic fractures increases with age, and is higher in women than in 
men. Women lose approximately 50 percent of their cancellous bone and 30 percent of 
their cortical bone during their lifetimes (Riggs and Melton, 1986), and nearly a third to 
one half of all bone loss in women may be attributable to the menopause (Riggs and 
Melton, 1992). Estrogen therapy, if begun at the menopause, can prevent the early loss 
of bone and decrease the incidence of ensuing osteoporosis-related fractures by about 50 
percent (Weiss et a/., 1980; Ettinger et al., 1985). Although the efficacy of estrogen has 
been demonstrated through numerous clinical trials (Christiansen et al. 1982; Lindsay et 
al., 1984; Ettinger et al., 1987; Adami et al. 1989), the mechanism of estrogen action on 
bone has not been clearly elucidated. 
Interestingly, certain partial estrogen antagonists such as tamoxifen have also 
been found to have anti-osteoporotic effects in bone. Among other indications, 
tamoxifen is used clinically as a chemotherapeutic agent to treat women with estrogen- 
receptor positive breast cancer. Actions of tamoxifen are, however, tissue specific, and 
despite opposing estrogen in breast, tamoxifen produces estrogen-like effects in other 
organs. Tamoxifen has been shown to reduce cardiovascular risk in post-menopausal 
women (Shewmon et al. 1994, Thanagaraju et al., 1994), induce proliferation of vaginal 
epithelium and, in higher doses, cause endometrial hypertrophy (Fornander et al., 1989, 
1991). Likewise, tamoxifen protects against the postmenopausal accelerated loss of bone 
mineral density (Love et al, 1992; Ward et al., 1993). An understanding of this partial 
agonist/antagonist activity of tamoxifen and related compounds would provide insight 
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into the pathogenesis of postmenopausal osteoporosis and provide opportunities for 
targeting estrogenic actions to specific tissues while minimizing side effects to others. 
Of much interest in the last decade of research has been the identification of local 
growth factors in bone and their interactions between hormones such as estrogen and 
other systemic factors. Central to this understanding is how these local factors effect the 
anabolic and catabolic balance in bone, as osteoblast and osteoclast activity are paired in 
a process of remodeling that occurs throughout the lifetime of an individual. In the 
normal adult skeleton, bone formation occurs at sites of previous resorption. Bone 
turnover occurs in a sequence of events known as activation-resorption-formation 
beginning with activation of osteoclastic precursors to become osteoclasts. During 
osteoclastic mediated resorption, cytokines and growth factors are released from the bone 
matrix which are then believed to recruit and activate osteoblasts to synthesize new bone. 
Osteoblasts also serve as intermediaries in the process of osteoclast activation, thereby 
maintaining a balance in the remodeling cycle Building and dissolving activities are thus 
coupled both temporally and quantitatively, as the amount resorbed is similar to that 
formed. The pathogenesis of postmenopausal osteoporosis stems from an imbalance in 
this remodeling cycle. With each cycle, more bone is resorbed than formed and 
excessive bone loss occurs, particularly in early menopause when osteoclastic activity is 
increased resulting in excess loss of cancellous bone (Turner et a/., 1994). As the 
skeleton ages, the slow phase of osteoporosis ensues and is characterized by decreased 
osteoblastic activity causing a decline in both cancellous and cortical bone mass. 
The coupling of osteoblast and osteoclast function is influenced by locally active 
factors. Among the more abundant of these growth factors found in bone are insulin-like 
growth factors (IGF’s), isolated initially from serum and named for observations which 
demonstrated insulin-like effects not suppressable by anti-insulin antiserum (Centreda et 
a/., 1993). Detectable in serum as well, systemic IGF is synthesized mainly by the liver 
and is under tight control by growth hormone (GH). However, numerous other tissues 
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including bone and cartilage also synthesize IGF’s active in the local environment in a 
paracrine or autocrine manner. Isolated bone cells in serum free cultures have been 
documented to produce at least two different types of IGF, termed IGF-I and IGF-II 
(McCarthy & Centrella,. 1993). IGF-I is identical to somatomedin-C, acting under 
control of GH to increase synthesis of sulfated proteoglycans in cartilage; IGF-II was 
found to be analogous to multiplication stimulating activity (MSA) mitogen (Centrella et 
a/., 1993). IGF-II appears to have lower biologic potency in isolated bone and bone cell 
cultures (McCarthy et ah, 1989; Centrella et al, 1990). Bone cells express at least two 
different cell surface receptors, type 1 and type 2, preferentially binding IGF-I and IGF-II 
respectively. In most tissues both factors appear to bind to type 1 receptor when effects 
are stimulatory (Centrella et al., 1993). Indeed it is believed that biological function of 
IGF-I and II occur via binding to type 1 receptor, supported by the finding that some 
organisms fail to bind IGF-II to type 2 receptor completely (McCarthy & Centrella, 
1994). 
Produced by osteoblasts and other bone cells, IGF-I has been shown to potently 
stimulate bone formation as well as to increase bone resorption In cultures of fetal rat 
calvariae, IGF-I has a mitogenic effect, increasing osteoprogenitor cell replication and 
resulting in larger numbers of osteoblasts. Further, IGF-I has a direct effect on 
osteoblasts, enhancing production of type I collagen and thus bone matrix (Hock et al., 
1988). IGF-I also decreases bone collagen degradation (Canalis, 1993). In contrast, IGF- 
I influences the number of osteoclasts, recruiting immature cells to become fully 
functioning osteoclasts. A study by Mochizuku et al. (1992) demonstrated that IGF-I 
stimulates not only recruitment but also activation of osteoclasts in mouse bone cell 
cultures. IGF-I was also shown to increase production of IL-6, a resorptive cytokine, in 
cultures of mouse long bones and osteosarcoma cells (Slootweg et al., 1992). Therefore, 
IGF-I appears to function as an agent that enhances bone turnover, possibly mediating 
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interactions between osteoblasts and osteoclasts and serving to coordinate the coupling of 
bone resorption and formation. 
Skeletal production of IGF-I responds to several systemic factors, including 
parathyroid hormone (PTH). A polypeptide hormone, PTH stimulates bone resorption by 
indirectly affecting osteoclasts via its actions on osteoblasts. PTH also influences bone 
formation. In cultures of fetal rat calvariae, effects of PTH were shown to be dependent 
on the method of administration. Continuous treatment with PTH for 24-72 hours results 
in inhibition of collagen synthesis. In contrast, intermittent treatment results in 
stimulation of IGF-I expression and increased collagen synthesis, an effect blocked by 
the addition of IGF-I antibodies (Canalis et al., 1989). Further experiments demonstrate 
a transient increase in the production of IGF-I mRNA in response to PTH treatment of 
osteoblast-enriched cell cultures of fetal rat bone (McCarthy et al., 1988). Other systemic 
factors, such as growth hormone GH, cause a small stimulation of IGF-I by skeletal cells 
(Canalis, 1993). Long term treatment with glucocorticoid, which clinically induces 
osteoporosis, results in decreased collagen synthesis in bone and inhibition of IGF-I 
production by osteoblasts (McCarthy eta/., 1988; Delany & Canalis, 1995). 
Of interest in understanding the pathogenesis of postmenopausal osteoporosis is 
the interaction of estrogen and different estrogen analogues with IGF-I. Earlier studies 
by Ernst et al. indicated that 17(3-estradiol has a small direct stimulatory effect on levels 
of IGF-I mRNA and collagen mRNA while decreasing PTH-stimulated adenylate cyclase 
activity in primary cell cultures of neonatal rat bone (Ernst et al., 1989; Ernst & Rodan, 
1991). In a recent study, Watson et al. (1995) demonstrated that levels of IGF-I mRNA 
in osteoblasts are nearly identical in intact and ovariectomized (OVX) rats. The OVX rat 
is an accepted model for human postmenopausal osteoporosis (Kalu, 1991b). Other in 
vivo studies, however, demonstrate that in the OVX rat IGF-I levels increase in serum as 
well as bone. This rise in IGF-I on both circulating and local levels is prevented by daily 
systemic estrogen therapy (Sato et al, 1993). Further, ovariectomy induces an increase 
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in osteoblast and osteoclast numbers and a loss of cancellous bone, effects that are all 
attenuated by 17[3-estradiol administration (Kalu et al., 1994). In a model system 
designed to study osteoblast activity, Yokose et al. (1996) concluded that bone formation 
is accelerated in OVX rats, a rise which is prevented by estrogen therapy. Serum from 
OVX rats induces proliferation and differentiation of osteoblast-like cells but the serum 
from OVX-estrogen treated rats does not. Furthermore, the addition of IGF-I neutralizing 
antibodies blocks almost completely the stimulatory effect of the OVX sera on DNA 
content, suggesting that IGF-I plays a role in the proliferation of osteoblasts or osteoblast 
precursors. 
Estrogen also influences the anabolic demands in bone, possibly via IGF-I acting 
as a coupling factor. 17|3-estradiol antagonizes TNF-a induced IL-6 production, an 
interleukin known to stimulate the recruitment and formation of osteoclasts (Girasole et 
al., 1992; Pottratz et al., 1994). Moreover, release of IL-1, another resorptive cytokine, 
increases in estrogen deficient states. This increase, demonstrated in blood monocytes 
derived from postmenopausal women and in spleen macrophages from OVX rats, returns 
to basal levels with systemic estrogen treatment (Sato et al., 1993). Also, as mentioned 
above, IGF-I stimulates IL-6 production in mouse osteosarcoma cell cultures. Therefore, 
estrogen suppression of IL-6 may be indirect through suppression of TNF-a, IL-I and 
IGF-I, as well as through direct suppression of IL-6 promoter activity. 
The mechanism of tamoxifen’s actions and its interactions with local coupling 
factors are also under investigation. Abundant evidence supports the estrogen agonist 
properties of tamoxifen on bone in states of estrogen deficiency. In vivo experiments 
illustrate a protective effect of tamoxifen similar to estrogen in maintaining cancellous 
bone volume in the treatment of OVX rats (Moon et al., 1991). Similarly, tamoxifen 
prevents resorption of endocortical and cancellous bone in the first month following 
ovariectomy in growing rats (Turner et al., 1988; Kalu et al., 1991a; Evans & Turner, 
1995), as well as preventing a decrease in bone volume over long-term treatment in 
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mature OVX rats (Turner et al., 1987) In clinical trials involving both healthy patients 
and women with breast cancer, tamoxifen prevents early postmenopausal bone loss at the 
lumbar spine and femur, as well as at the iliac crest (Ward et al., 3 993; Wright et al., 
1993). In postmenopausal women with breast cancer, tamoxifen has even been shown to 
significantly increase bone mineral density in the spine by 0.61% per year compared to a 
1 00% decrease in patients treated with placebo (Love et al., 1992). In a trial of 
chemoprevention of breast cancer in healthy postmenopausal patients, tamoxifen also 
increased the bone mineral density (BMD) in the hip by 1.71% compared to a 
nonsignificant loss in women administered placebo (Powles et al., 1996). 
Tamoxifen’s role in the premenopausal state, however, is not completely 
understood. On the one hand, tamoxifen has been shown to have increased antiestrogenic 
activity in premenopausal subjects. Studies in OVX versus non-OVX rats demonstrate a 
small increase in uterine weight in tamoxifen treated OVX rats. In contrast, tamoxifen 
has an antiestrogenic effect in non-OVX rats causing a small decrease in uterine weight 
(Moon et al., 1991). Administration of estrogen and tamoxifen to OVX rats results in 
slightly decreased effectiveness of the bone-sparing properties of estrogen, suggesting 
that tamoxifen may be competing with native estrogen for binding and activation of the 
estrogen receptor (Kalu et al., 1991a). Furthermore, a recent study using tamoxifen as a 
chemopreventative agent in healthy premenopausal women revealed that it significantly 
decreased BMD in the hip and lumbar spine (Powles et al., 1996). In the same study, 
however, tamoxifen increased bone mineral density in both sites in postmenopausal 
patients. Once again this suggests that tamoxifen may exhibit different effects depending 
upon existing estrogen levels. This is perhaps partially because the effects of tamoxifen 
may be less potent and therefore the level of activation of the estrogen receptor may be 
diminished in comparison to estrogen. 
On the other hand, previous smaller clinical trials did not note a significant 
difference of tamoxifen and placebo on the BMD of the radius in premenopausal patients 
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with breast cancer (Gotfriedsen eta/., 1984). Nor was there a significant difference in the 
BMD of the spine or hip in premenopausal women receiving either tamoxifen or placebo 
for mastalgia (Fentiman et al., 1989). Other in vivo studies also note no significant 
difference in bone sparing effects by tamoxifen in the treatment of OVX versus intact rats 
(Goulding & Gold, 1994). Tamoxifen is even reported to enhance the effects of estrogen 
on increasing trabecular bone mass in both OVX and non-OVX rats (Turner et al., 
1988), in direct conflict with results noted above. Further work is required to elucidate 
the interaction of endogenous estrogen and the effects of native estrogen levels with the 
actions of tamoxifen, particularly as premenopausal women could suffer deleterious 
outcomes from prolonged antiestrogen therapy. 
On the local level, the actions of tamoxifen on osteoblast and osteoclast activity 
are similar to estrogen in states of estrogen deficiency. Tamoxifen has been shown to 
prevent the production of osteoclasts by inhibiting the fusion of osteoclast precursors 
(Turner et al., 1987; Turner et al., 1988; Turner et al., 1993) as well as decreasing the 
numbers of osteoclasts in OVX rats (Isserow et al, 1994). As with postmenopausal 
estrogen therapy, long-term tamoxifen treatment of women with breast cancer decreases 
the bone turnover rate, causing a longer remodeling period, lower bone formation rate, 
and smaller resorption cavities in cancellous bone (Wright et al., 1994) Like estrogen, 
tamoxifen decreases serum levels of osteocalcin (Ward et al, 1993; Williams et al, 
1991; Fornander et al, 1993), an osteoblast-restricted protein that correlates positively 
with levels of bone formation (Brown etal, 1984). 
While little is known regarding tamoxifen effects on IGF-I expression in bone, 
tamoxifen has estrogenic effects on the liver (Evans & Turner, 1995). Serum levels of 
IGF-I in postmenopausal women receiving adjuvant tamoxifen therapy decrease, (Grady 
et al., 1992; Fornander et al, 1993) as do circulating levels of lipoprotein A, serum 
cholesterol and other lipids (Shewmon et al., 1994; Thanagaraju et al., 1994). Tamoxifen 
also reduces IGF-I levels locally in lung, a common organ for breast cancer metastasis 
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(Huynh et al., 1993a). Tamoxifen, however, increases IGF-I gene expression in the rat 
uterus. Yet this action is also consistent with estrogen, for the pure anti-estrogen ICI 
182780 (ICI) reduces IGF-I uterine activity (Huynh & Poliak, 1993b). With regards to 
bone, OH-tamoxifen decreases TNF-cx induced LL-6 expression in mouse osteosarcoma 
cell cultures as does estrogen (Galien el al., 1996). As little is known of the mechanism 
of tamoxifen action in bone cells, our present study aimed to elucidate the effects of 
tamoxifen in influencing IGF-I expression compared to previous reports of estrogen 
modulation of IGF-I in cultures of fetal rat osteoblasts. 
Agents such as PTH and prostaglandin E2 (PGE2) that increase intracellular cyclic 
adenosine 3’,5’-monophosphate (cAMP) concentrations stimulate IGF-I expression 
(McCarthy et al, 1991; Bichell et al, 1993; Pash et al, 1995). An eicosanoid, PGE2 
synthesis by osteoblasts is increased by PTH, mechanical stress, and various other growth 
factors (Pash et al., 1995). Treatment of osteoblast enriched cultures isolated from fetal 
rat calvariae with varying concentrations of PGE2 results in an elevation of intracellular 
cAMP and a rise in IGF-I mRNA transcripts, evident within 30 minutes of treatment 
(McCarthy et al., 1991). PGE2 enhances IGF-I transcription via interaction with 
promoter 1 of the rat IGF-I gene (Bichell et al., 1993; Pash et al., 1995) . Similar to 
humans, the rat IGF-I gene consists of approximately 80 kilobases of DNA divided into 
six exons and five introns (Rotwein, 1991). Although the gene has two promoters, 
promoter 1 is active in all tissues in which IGF-I is expressed; promoter 2 is most active 
in the liver Only promoter 1 is functional in fetal rat osteoblasts . 
Genes regulated by cAMP typically contain a cAMP response element (CRE) 
within their promoters or AP-2 sites to which CRE-binding proteins (CREB’s) or 
activator protein-2 transcription factors may respectively bind. CREB’s are activated by 
protein kinase A (PKA) dependent phosphorylation. PGE2 stimulated expression of IGF- 
I is PKA dependent, as demonstrated by experiments where co-transfection with a 
dominant negative mutant PKA regulatory subunit unable to bind cAMP ablates the 
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response of osteoblasts to PGE2 (McCarthy et a/., 1995). Although the IGF-I promoter 1 
contains a single, near consensus CRE and several potential binding sites for transcription 
factor AP-2, deletion of these regions does not block PGE2 induced stimulation of IGF-I 
promoter activity. Rather, a portion of the 5’-untranslated region (UTR) of exon 1 
containing a region termed HS3D (from the notation of the DNase I footprinted site), 
with no nucleotide sequence similarity to the consensus CRE, is integral to PGE2 
stimulation of IGF-I (Thomas et al, 1996). Furthermore, gel mobility shift studies with 
nuclear and cytoplasmic cell extracts indicate that nuclear proteins interact with specific 
nucleotides within the HS3D DNA sequence, and that active factors are not present in the 
cytoplasm. Treatment of cultures with the protein synthesis inhibitor cycloheximide does 
not inhibit the effect of PGE2 on IGF-I mRNA, and does not interfere with the PGE2- 
induced binding of the nuclear proteins to the HS3D DNA sequence These findings 
suggest that PGE2 activates a pre-existing DNA-binding protein (Thomas et ai, 1996). 
Current work by Dr. McCarthy indicates that 17(3-estradiol inhibits PGE2 induced 
IGF-I expression not by interfering with cAMP production but possibly by altering 
protein-protein interactions between the PKA activated transcription factors and the 
estrogen receptor (ER) (McCarthy et al., 1997). Estrogen can affect cellular events by 
binding to an intracellular receptor, the ER, that can function as a transcription factor 
(Evans, 1988; Beato, 1989). Typically, the ER-ligand complex binds to DNA at estrogen 
response elements (ERE’s) to modulate gene expression (Ham & Parker, 1989), although 
alternate mechanisms independent of ERE interaction are being investigated Treatment 
of fetal rat osteoblast cell cultures with 17(3-estradiol alone has no effect on IGF-I 
expression, unlike the small stimulatory effect in neonatal cultures described by Ernst et 
al. (1988), as discussed previously. Co-treatment of cells with PGE2 and 17(3-estradiol, 
however, results in a potent, dose-dependent suppression of IGF-I promoter 1 activity 
that is ER dependent and estradiol isomer selective (McCarthy et al., 1997). 
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In order to further elucidate the mechanism of estrogen action and to begin to 
understand the tissue selective effects of antiestrogens, we have investigated the actions 
of tamoxifen on IGF-I promoter activity. Consistent with the anti-osteoporotic effects of 
tamoxifen on bone, we hypothesized that tamoxifen would also suppress the PGE2 
stimulation of IGF-I expression. Primary cell cultures of fetal rat osteoblasts were 
transfected with IGF-I promoter 1 constructs with a luciferase reporter gene and human 
ER. A luciferase reporter was used to determine the activity of the IGF promoter very 
specifically, as luciferase is not native to osteoblasts. Although osteoblasts contain ER’s, 
(Eriksen et al., 1988; Komm et al., 1988; Ernst et a/., 1991b) cells are routinely 
transfected with ER in order to ensure the expression of active estrogen receptors. 
Transfected osteoblasts were then treated with vehicle, PGE2, or with 17P-estradiol or 4- 
hydroxy-tamoxifen (OH-tamoxifen) (an active metabolite of tamoxifen found in the 
serum of tamoxifen treated patients) both with and without PGE2. Nuclear extracts of 
cells treated in a similar manner were prepared and used in gel-mobility shift assays with 
a ,2P-labeled oligonucelotide probe comprising region HS3D of the IGF-I promoter, 
containing the nonconsensus CRE required for PGE2 stimulation. Our results indicate 
that, although tamoxifen behaves similarly to estrogen, it is not as potent at influencing 
cAMP activated IGF-I expression. Gel-mobility shift studies provide evidence of 
tamoxifen suppression of IGF-I promoter function via a similar mechanism of action as 
estrogen. Further work is required to elucidate tamoxifen’s and estrogen’s apparent non- 
genomic suppression of PGE2 induced IGF-I expression. 
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MATERIALS AND METHODS 
Cell Cultures Primary osteoblast cell cultures were prepared from parietal bones of 22- 
day old Sprague-Dawley rat fetuses (Charles River Breeding Laboratories, Raleigh, NC). 
All animals were euthanized in accordance with guidelines set by the Yale University 
Animal Care and Use Committee. Cranial sutures were removed by dissection, and 
bones were digested for five 20-minute intervals with collagenase. The last three 
populations of cells were pooled and plated at 6,250-8,000 per cm2 in Dulbecco’s 
modified Eagle’s medium (DMEM) containing 20 mM N-2 hydroxyethylpiperazine-N’- 
2-ethanesulfonic acid (HEPES) buffer (pH 7.2), 0.1 mg/ml ascorbic acid, penicillin and 
streptomycin (all from Life Science Technologies, Gaithersburg, MD), and 10% fetal 
bovine serum (FBS) (Sigma Chemical Co., St. Louis, MO). During and following 
transfection, cultures were maintained in phenol-red free (PRF) DMEM. Likewise, after 
transfection, cells were grown in charcoal stripped FBS containing PRF-DMEM and all 
treatments were carried out in serum-free PRF-DMEM. To maintain consistency 
throughout the laboratory, cell cultures were routinely prepared by Sandra Casinghino 
and plated by Dr. Thomas L. McCarthy or Sandra Casinghino. 
Plasmids A recombinant luciferase reporter construct containing two tandem estrogen 
response elements (ERE from the vitellogenin gene) along with a segment of the 
prolactin promoter ((ERE^-PRL-Luc) and a Rous sarcoma virus promoter expression 
plasmid containing the human estrogen receptor (pRSV-hER) were provided by Dr. 
Stuart Adler (Washington University School of Medicine). Plasmid pGL3 control is a 
reporter vector that utilizes the promoter and enhancer of Simian virus 40 to allow for 
high level expression of the luciferase reporter gene, thereby serving as a positive control 
for the transfections. Plasmid p(j>Luc is a parental, promoterless luciferase reporter vector 
into which the IGF-I promoter 1 segment was cloned. IGF-171 lb-Luc plasmid contains 
1711 base pairs (bp) of 5’upstream sequence of the IGF-I promoter 1, along with 328 bp 
of 5’transcribed and untranslated sequence from exon 1. All plasmids were propagated in 
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E. coli strain DH5a with ampicillin selection and purified by Sandra Casinghino using a 
Wizard Plus Maxiprep DNA Purification Kit according to the manufacturer’s 
recommended protocol. Recombinant human ER plasmid was prepared by Kristina 
Crothers, by modification of the alkaline extraction method (Nicoletti & Condorelli, 
1993). Briefly, E. coli cultures transformed with hER plasmid were grown with 
ampicillin selection, harvested, and washed in STE (100 mM NaCl, 10 mM Tris-HCl, pH 
8.0, 1 mM EDTA). Cells were then pelleted and resuspended in 50 mM glucose, 25 mM 
Tris-HCl, pH 8.0, 10 mM EDTA solution. NaOH-SDS solution (200 mM NaOH, 1% 
SDS) was used to lyse the cells on ice and denature E. coli genomic DNA; the solution 
was neutralized with the addition of sodium acetate. After centrifugation, the supernatant 
was filtered and the plasmid was ethanol precipitated (2 volumes ethanol added). The 
pellet was resuspended in TE (10 mM Tris-HCl, pH 8 0, 1 mM EDTA) and RNA 
digested with RNase. Proteins were removed by a phenol:chloroform:isoamyl alcohol 
extraction followed by a chloroformisoamyl alcohol extraction to reduce phenol 
contamination of the aqueous phase. The DNA was ethanol precipitated, resuspended in 
TE and the degraded RNA eliminated by 40% PEG-6000 (30 mM MgCl2) precipitation. 
Two 70% ethanol washes to remove the residual PEG followed. The pellet was air dried 
and resuspended in TE and the plasmid DNA quantified by optical density absorbance at 
260 nM using a UV spectrophotometer. 
Transfection Studies Cultures were grown to approximately 50% confluent density, 
rinsed in serum-free PRF-DMEM and exposed to plasmids in the presence of 0 5% 
Lipofectin ™ (Life Science Technologies). Each plasmid was used at a final 
concentration of 1.25 gg/9.6 cm2 culture well in the following combinations: pGL3 
control co-transfected with hER, p(f>Luc co-transfected with hER, (ERE)2PRL-Luc with 
and without hER, and IGF-171 lb-Luc co-transfected with hER. Plasmid combinations 
and individual treatment conditions were performed in replicates of three in every 
experiment. After 3 hours of incubation, the plasmid solutions were aspirated and 
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replaced with growth medium containing PRF-DMEM with 5% charcoal stripped FBS. 
Cultures were allowed to grow for 48 hours. Prior to treatment with test agents, cultures 
were rinsed with serum-free PRF-DMEM and then treated for indicated times with either 
vehicle (ethanol at 1/1000 dilution), PGE2 (1 pM), 17(3-estradiol (10 nM) either alone or 
in combination with PGE2, or 4-hydroxy-tamoxifen (OH-tamoxifen) (in concentrations as 
indicated) either alone or in combination with PGE 2. At the end of the treatment interval, 
cultures were rinsed with phosphate buffered saline (PBS), and then lysed in 100 pi of 
Cell Lysis Buffer (Promega Corp.) containing 25 mM Tris-phosphate (pH 7.8), 2 mM 
dithiothreitol (DTT), 2 mM 1,2-diaminocyclohexane-N, N, N’, N’-tetraacetic acid, 10% 
glycerol (to stabilize enzymes for freezer storage), 1% Triton-X-100 (to lyse cell 
membranes). Lysates were collected and centrifuged at 12,000 x g for 5 minutes to pellet 
nuclei. Supernatants were collected and stored at -75°C until assayed Luciferase 
reporter enzyme activity was measured in a Packard scintillation spectrometer by single 
channel photon counting employing a commercial kit from Promega Corp. according to 
manufacturer’s instructions. Protein content of each cell extract was determined by 
Bradford dye binding assay, using bovine serum albumin to generate a standard curve. 
Luciferase activity was corrected for protein content Most transfections were performed 
by Kristina Crothers; experimental results were corroborated by Sandra Casinghino and 
Dr. Thomas L. McCarthy 
Nuclear Protein Extracts Cultures were grown to 40% confluent density, rinsed in 
serum-free PRF-DMEM and exposed to 20 pg hER plasmid per 177 cm2 culture plate 
(150 mm) in the presence of 15 ml containing 0.5% Lipofectin™ (Life Science 
Technologies). After 3 hours, the plasmid solutions were aspirated and replaced with 
PRF-DMEM containing 5% charcoal stripped FBS and allowed to grow for 48 hours. 
Prior to treatment with test agents, cultures were rinsed with serum-free PRF-DMEM and 
then treated for 4 hours with either vehicle (ethanol at 1/1000 dilution), PGE2 (1 pM), 
17p-estradiol (10 nM) either alone or in combination with PGE2, or OH-tamoxifen (1 
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|xM) either alone or in combination with PGE2. Previous experiments in our laboratory 
demonstrated that 17(3-estradiol suppressed PGE2 induced binding to HS3D, the atypical 
CRE, within 4 hours as determined by gel mobility shift assay. The treatment solutions 
were then aspirated and cultures were rinsed twice with PBS at 4°C; all subsequent steps 
were performed on ice. Using a sterile cell scraper, cells were harvested in PBS and 
gently pelleted at 3000 rpm, washed with PBS and repelleted. Cells were then 
resuspended in hypotonic buffer containing 1% Triton X-100, 10 mM HEPES (pH 7.4), 
1.5 mM MgCl2, 10 mM KC1, 0.5 mM DTT, 1 mM sodium orthovanadate, and protease 
inhibitors (0.5 mM phenyl methylsulfonyl fluoride, 1 pg/ml pepstatin A, 2 pg/ml 
leupeptin, and 2 pg/ml aprotinin, all from Sigma Chemical) to gently lyse the cells. 
Nuclei were pelleted at 3500 rpm. The lysates were resuspended in hypotonic buffer as 
above, and repelleted to achieve complete lysis and to wash the nuclei in order to reduce 
the level of membrane bound alkaline phosphatase in the nuclear fraction. Nuclear 
proteins were released in hypertonic buffer containing 0.42 M NaCl, 0.2 mM disodium 
ethylenediamme tetraacetic acid, 25 % glycerol, and sodium orthovanadate and protease 
inhibitors as above. After 30 minutes of incubation, the nuclear debris was pelleted at 
13,000 rpm for 5 minutes and the supernatant containing the nuclear protein extracts were 
aliquoted and stored at -75°C until gel-shift analysis was performed. Protein 
concentrations were determined by Bradford dye binding assay. Buffer solutions were 
provided by Chang-Hua Ji; all nuclear extracts were prepared by Kristina Crothers. 
Electrophoretic Mobility Shift Assay Gel-shift assays were performed as described 
previously (Revzin, 1989; Carey, 1991; Thomas, 1996). Briefly, a radiolabeled double- 
stranded oligonucleotide probe (sequence shown below) (Universal DNA Inc., Tigard, 
OR) was prepared by annealing complimentary nucleotides in 10 M Tris-Cl (pH 8.0), 1 
mM EDTA, and 5 mM MgCl2 by heating to 95°C then cooling to room temperature over 
a one hour time period. Using the Klenow fragment of E. coli DNA polymerase I, single- 
stranded overhangs were filled in with dCTP, dGTP, dTTP, and [cx-32P]dATP at room 
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temperature. The probe was then gel purified prior to use. 5 pg of each nuclear protein 
extract was incubated in binding buffer (25 mM HEPES pH 7.5, 50 mM KC1, 2 mM 
dithiothreitol, 0.5 mg/ml bovine serum albumin, and 12 5% glycerol) containing 1.25 pg 
poly(dI/dC) (Sigma) on ice. After 10 minutes, 0.1 ng (approximately 3 x 104 cpm) of 
42P-labeled HS3D DNA probe was added for a total reaction volume of 20 pi and 
incubated on ice for an additional 30 minutes. A 5% nondenaturing polyacrylamide gel 
was preelectrophoresed for 30 minutes at 12.5 V/cm at 25°C in 45 mM Tris, 45 mM 
boric acid, 1 mM EDTA, pH 8.3. Samples were then loaded onto the gel and 
electrophoresis proceeded under identical conditions for 2.5 hours. The gel was then 
dried and exposed to X-ray film at -75 °C with an intensifying screen. Labeled HS3D 
probe was prepared by Chang-Hua Ji; gel-shifts were performed by Kristina Crothers. 
The sense strand oligonucelotide sequence of HS3D with response element 
underlined is shown below. 
5 ’ -GAGC AGAT AGAGCC TGCGCAATCG A AATA-3 ’ 
Reagents Cell culture reagents were obtained from Life Science Technologies 
(Gaithersburg, MD) and Sigma Chemical Co. (St. Louis, MO) 17(3-estradiol and PGE2 
were obtained from Sigma Chemical Co OH-Tamoxifen was obtained from Research 
Biochemical International (Natick, MA). 
Statistical Analysis Data from transfections were reported in triplicate for each 
condition; results are reported as means +/- S.E. Statistical analysis was performed using 
the SigmaStat computer software package, using the one-way analysis of variance 
(ANOVA) to determine significance. Results of the electrophoretic mobility shift assay 





17(3-estradiol effects on IGF-I activity 
Primary cultures of fetal rat osteoblasts were transfected with the IGF-I promoter 
1-luciferase reporter construct, IGF 171 lb/Luc. This construct contains an atypical cAMP 
response element (CRE) required for the PGE2 stimulated rise in IGF-I via a cAMP 
dependent mechanism (Thomas et al, 1996). Cells were co-transfected with hER 
expression vector, required for estrogen as well as tamoxifen action. Previous work by 
Dr McCarthy illustrated that, at a concentration of 1 pM, PGE2 stimulates IGF-I 
transcription an average of 4- to 5-fold after 6 hours of exposure. Furthermore, this effect 
is dose-dependently suppressed by 17(5-estradiol, and sustained over 16 hours of 
treatment (Fig. 1, adapted from McCarthy et al, 1997). Inhibition is hER dependent, as 
it is not observed in the absence of hER co-transfection. This effect is estradiol isomer 
specific, as 17a-estradiol is 100-300 fold less potent. Experiments repeated in this thesis 
confirm that PGE2 produces nearly 6-fold stimulation of IGF-I promoter activity which 
can be reduced by 10 nM 17(3-estradiol after 6 hours of co-treatment, with no effect on 
IGF-I activity by estrogen alone (Fig. 2). Thus 17(3-estradiol served as an internal control 
in appropriate experiments. 
OH-tamoxifen effects on IGF-I activity 
To investigate the effects of tamoxifen on IGF-I expression, all experiments 
reported in this thesis used 4-hydroxy-tamoxifen (OH-tamoxifen), in agreement with 
other investigations of tamoxifen (Galien et al., 1996). This is an active metabolite of 
tamoxifen formed in vivo in both animal models and in the serum of breast cancer 
patients treated with tamoxifen, and is reported to be 100- to 1000-fold more potent than 
tamoxifen (Borgna& Rochefort, 1980; Rochefort, 1991; Pujol et cil., 1995). Cell cultures 
were treated for 6 hours with 1 pM PGE2 with or without equal concentrations of OH- 
tamoxifen or estrogen (both 10 nM). Neither 17(3-estradiol nor OH-tamoxifen alone had 
any effect on IGF-I promoter activity when compared to vehicle (ethanol diluted 1/1000). 
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The 6-fold PGE2 stimulation was significantly reduced by the addition of 10 nM 17[3- 
estradiol but was unaffected by the addition of 10 nM OH-tamoxifen (Fig. 2). 
Given that tamoxifen is a therapeutic agent and not a physiologic hormone as is 
estrogen, pharmacologic doses of OH-tamoxifen were next used to determine if higher 
doses might suppress the PGE2 induction of IGF-I as effectively as 17(3-estradiol. 
Overall, concentrations from 0.1 nM to 1 pM were tested Results from five experiments 
were pooled (Fig. 3). Like estrogen, tamoxifen suppressed PGE2 induced IGF-I promoter 
activity in a dose dependent manner At concentrations of l pM, OH-tamoxifen 
significantly (p<0.05) reduced promoter activity by 70%. Once again, 1 nM 
concentrations of tamoxifen were not significantly inhibitory, compared to 64% 
inhibition seen with the same concentration of 17(3-estradiol (Fig. 3). OH-tamoxifen 
alone at these higher doses had no significant effect on IGF-I promoter activity. These 
initial findings indicate that tamoxifen, while capable of suppressing IGF-I activity, 
appears to be less potent in its behavior on osteoblasts than 17p-estradiol 

IGF-I Promoter Activity 
17p-estradiol 
Figure 1. 17(3-estradiol dose dependently suppressed PGE, stimulated IGF-I 
promoter 1 activity in osteoblast cell cultures expressing hER. IGF-I promoter 1 
luciferase reporter plasmid, IGF 171 lb-Luc, was co-transfected with hER into 
osteoblast cultures. Cultures were grown in phenol red-free DMEM containing 5% 
charcoal-stripped FBS for 48 hours. The growth medium was aspirated, and cultures 
rinsed with phenol red-free, serum-free DMEM. Cultures were treated with control 
medium (ethanol at 1/1000 dilution), PGE0 (1 pM), 0.01 to 10 nM 17(3-estradiol, or 
both agents for 16 hours. 17a-estradiol (10 nM) was used both with and without 
PGE2 (1 pM) to test for estrogen isoform specificity. Cytoplasmic extracts were 
prepared and luciferase activity determined. Data are corrected for protein content. 
Transfections were performed in triplicate, and results are representative of 3 separate 
experiments. The mean +/- SE for luciferase expression (cpm per pg protein) are 
shown. 

IGF-I Promoter Activity 
Figure 2. As with 17p-estradiol treatment, 4-OH-tamoxifen treatment of 
osteoblast cell cultures had no effect on IGF-I promoter activity. Unlike estrogen, 
an equal concentration of 4-OH-tamoxifen did not suppress PGE2 stimulation of 
the IGF promoter 1. Osteoblast cell cultures were transfected as described in Figure 1 
and Materials and Methods. Cultures were treated with vehicle (1/1000 ethanol), I pM 
PGE2, 10 nM 17p-estradiol in the absence or presence of PGE^, or 10 nM 4-OH- 
tamoxifen in the absence or presence of PGE2. After 6 hours, cell extracts were 
prepared and luciferase activity determined. Data are corrected for protein content. 
Transfections were performed in triplicate. Results of a representative experiment, +/- 
SE, are shown. 

IGF-I Promoter Activity 
4-OH-Tamoxifen 
Figure 3. 4-OH-tamoxifen dose dependently suppressed PGE2 stimulated 
IGF-I promoter 1 activity in osteoblast cultures expressing hER. Osteoblast 
cell cultures were transfected as described in Figure 1 and Materials and Methods. 
Cells were treated for 6 hours with varying concentrations of 4-OH-tamoxifen both 
with and without PGE2 (1 pM). Luciferase activity of cytoplasmic extracts was 
determined, and data were corrected for average protein content. Data represent 
pooled results from 5 experiments (n = 9-15). At 1 pM and 0.1 pM 
concentrations, tamoxifen suppression of PGE2 induced IGF-I expression was 
statistically significant (*, p < 0.05). 
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Comparison of OH-tamoxifen to 17(3-estradiol stimulation of the ERE 
To address whether the inhibitory effects of the higher doses of OH-tamoxifen 
could be due to toxic effects on the fetal rat osteoblasts, cultures were co-transfected with 
hER and a recombinant reporter plasmid containing two tandem copies of the consensus 
estrogen response element (ERE) and a segment of the prolactin promoter controlling the 
expression of the luciferase reporter ((ERE)2PRL-Luc). Previously, a 6 hour treatment 
with 10 nM 17(3-estradiol of cultures transfected with ERE2PRL-Luc demonstrated on 
average a 5-fold stimulation (McCarthy et al., 1997). It was unclear initially whether 
OH-tamoxifen would behave similarly. As with 17(3-estradiol stimulation, OH- 
tamoxifen activation of the ERE required co-transfection with hER, as cells not 
transfected with the hER expression vector were unable to respond to either OH- 
tamoxifen or 17(3-estradiol (Fig. 4). However, the stimulation by tamoxifen appeared 
much weaker than that observed with estrogen. 
To determine the dose response of the ERE activation, transfected cultures were 
treated for 6 hours with varying concentrations of OH-tamoxifen, ranging from 1 pM to 
0.1 nM. These experiments consistently reveal that OH-tamoxifen was weakly 
stimulatory of the ERE containing plasmid only at the highest doses tested. While 10 nM 
17(3-estradiol enhanced transcription of this construct on average 3- to 5-fold, OH- 
tamoxifen was 200- to 350-fold less potent, only increasing activity 1.3 fold at 1 pM 
concentration (Fig. 5). This weak stimulation was statistically significant (p < 0.05), but 
became indistinguishable from control treatment at lower concentration of OH- 
tamoxifen. Prolonged treatment of (ERE)2PRL-Luc transfected cultures with 1 pM OH- 
tamoxifen resulted in a nearly 50% increase in activity, from a stimulation of 1.3 fold 
compared to control values after a 6 hour treatment to a nearly 1.9 fold enhancement of 
activity after 24 hours of treatment. This weak activation of the ERE-construct 
demonstrates that higher concentrations of OH-tamoxifen were likely not toxic to the 
cell cultures, even after 24 hours of exposure. These data support the conclusion that 
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tamoxifen acts as a partial estrogen agonist in osteoblasts, but is less potent than 17(3- 
estradiol 
17(3-estradiol and OH-tamoxifen effects on the parental, promoterless luciferase 
reporter construct 
Cells were transfected with the parental luciferase reporter construct that 
contained no promoter or ERE, and only the luciferase reporter gene (p(J)Luc). Cell 
cultures were then treated for 6 hours with vehicle, PGE2, 17(3-estradiol, or OH- 
tamoxifen, both with and without PGE2. Luciferase values were at background levels 
with each treatment condition (Fig. 6), confirming that luciferase activity is promoter 
dependent, and requires control by either the IGF-I promoter or (ERE)2PRL construct 
transfected into the cell cultures to detect any response to these test agents. 

(ERE)2PRL-Luc Activity 
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Figure 4. As with 17(3-estradiol, tamoxifen action is dependent on expression 
of hER. However, 4-OH-tamoxifen stimulation of the ERE is much less potent 
than 17p-estradiol. Cells were transfected with a recombinant luciferase reporter 
construct containing tandem copies of the consensus ERE and a segment of the 
prolactin promoter, ((ERE)2PRL-Luc), both with and without hER. Cultures were 
treated with vehicle (ethanol at 1/1000 dilution), 17(3-estradiol (10 nM), or 4-OEl- 
tamoxifen (1 pM). After 6 hours, cytoplasmic extracts were prepared and luciferase 
activity determined. Data are corrected for protein content. Transfections were 
performed in triplicate, and results shown are representative of one experiment. 
The mean +/- SE for luciferase expression (cpm per pg protein) are shown. 

(ERE)2PRL-Luc Promoter Activity 
4-OH-Tamoxifen 
Figure 5. 1 pM 4-OH-tamoxifen weakly stimulated the (ERE)2PRL-Luc 
promoter. Osteoblasts were transfected as described in Figure 4 and Materials 
and Methods with the (ERE)2PRL-Luc construct and hER. Cells were treated 
for 6 hours with 1 nM to 1 pM 4-OH-tamoxifen. Cytoplasmic extracts were 
prepared and luciferase activity determined. Data are corrected for average 
protein content. Results represent data pooled from 8 experiments (n = 12-24). 
Stimulation of the ERE promoter construct by 1 pM tamoxifen was 
statistically significant (*, p < 0.05). 











Figure 6. PGE2 stimulation was specific for the IGF-I promoter 1; estrogen 
and tamoxifen stimulation was specific for the ERE. Osteoblasts were 
transfected with the promoterless, parental expression vector pOluc or pGL3 control 
vector as described in Materials and Methods. Cells were treated for 6 hours with 
vehicle, 1 pM PGE2, 10 nM 17(3-estradiol with and without PGE2, or 1 pM 4-OH 
tamoxifen, both with and without PGE0. Cytoplasmic extracts were prepared, and 
luciferase activity determined. Transfections were performed in triplicate. Results 
of a representative experiment are shown. 
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Nuclear protein extractions tested in electrophoretic mobility shift assays 
A gel mobility shift assay was conducted using a 32P-labeled oligonucleotide 
containing the IGF-I CRE, termed HS3D, and nuclear extracts of cell cultures transfected 
with hER. Nuclear extracts from cultures treated with 1 pM PGE2 caused an inducible 
gel-shift, demonstrating cAMP activated transcription factor binding to the nonconsensus 
CRE in the IGF-I promoter 1 with no detectable interference by hER expression 
(McCarthy el a/., 1997). Consistent with previous findings in the laboratory, co¬ 
treatment of cells with PGE2 and 17(3-estradiol (1 nM) caused a reduction in the intensity 
of PGE2 induced gel shift bands, with no alteration in the banding pattern (Fig. 7) 
Treatment of cells with either 17(3-estradiol or OH-tamoxifen alone did not produce an 
appreciable change compared to control cultures. A preparation of nuclear extract from 
cells co-treated with both PGE2 and OH-tamoxifen (1 pM) for 4 hours tested with the 
32P-HS3D oligonucleotide also induced a gel-shift, with reduced band intensity when 
compared to that induced by PGE2 treatment alone Analysis of band density indicates 
that OH-tamoxifen reduced the PGE2 induced bands by 32%, while co-treatment with 
17|3-estradiol and PGE2 resulted in a decrease in band density by 47%. These results 
further confirm that OH-tamoxifen is less potent than 17(3-estradiol at inhibiting PGE2 
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Figure 7. 4-OH-tamoxifen was not as potent as 17(3-estradiol in suppressing 
the PGE2 induced binding of nuclear protein(s) to the IGF-I promoter 1 
atypical CRE. Electrophoretic mobility shift experiments were performed as 
described in Materials and Methods with nuclear extracts from osteoblast cultures. 
All osteoblast cultures were transfected with hER; cultures were treated with 
PGE2, 10 nM 17(3-estradiol with or without PGE2, or 4-OH-tamoxifen with or 
without PGE2 for 4 hours, as indicated above each lane. By analysis of band 
density, estrogen suppressed the PGE2 induced bands by 47%, while tamoxifen 




Although estrogen replacement therapy has been clinically proven to prevent the 
accelerated postmenopausal loss of bone, its mechanism of action remains incompletely 
understood. Accumulating evidence suggests that estrogen may act as a suppressive 
agent to maintain bone turnover at physiologically appropriate levels. Estrogen 
antagonizes IL-6 production (Girasole et al, 1992; Pottratz et al, 1994), as well as 
returning the release of IL-1 to premenopausal levels (Sato et al, 1993). On the other 
hand, estrogen also counters the postmenopausal or post-OVX rise in IGF-I both 
systemically and locally in bone tissue, as well as decreasing the rate of bone formation 
in OVX rats (Sato et al, 1993; Kalu et al., 1994; Yokose et al, 1996). Although it is a 
potent stimulator of bone formation, IGF-I also enhances bone resorption by recruitment 
of osteoclasts ((Mochizuki et al, 1992). Interestingly, IGF-I was shown to increase IL-6 
production in cultures of mouse long bones and osteosarcoma cells (Slootweg et al, 
1992). In combination with results from our laboratory demonstrating estrogen mediated 
suppression of PGE2 induced activation of the IGF-I promoter, these pieces of 
information suggest a role for estrogen in maintaining a basal rate of bone turnover which 
then becomes accelerated in states of estrogen deficiency. This tonic balance of anabolic 
and catabolic activity may be mediated in part by IGF-I, a known coupling factor for 
bone remodeling. 
Estrogen antagonists/agonists are becoming increasingly studied as possible 
therapeutic agents to target estrogenic effects to select tissues such as bone in order to 
prevent postmenopausal osteoporosis while minimizing side effects to other organ 
systems. Although used clinically as an antiestrogen to treat women with breast cancer, 
tamoxifen does not accelerate bone loss in these patients. Indeed, tamoxifen behaves as 
an estrogen agonist in bone tissue, but whether its mechanism of action is the same as 
that of estrogen is unclear. To begin answering these questions, this study investigated 
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the effects of tamoxifen in comparison to estrogen on IGF-I promoter function in primary 
cell cultures of fetal rat osteoblasts. 
Current work in the laboratory of Dr. McCarthy investigates the mechanism by 
which estrogen modulates the PGE2 stimulation of IGF-I gene promoter activity. This 
study confirms earlier results and demonstrates that treatment of fetal rat osteoblast cell 
cultures with 17(3-estradiol alone has no effect on IGF-I expression, contrary to previous 
in vitro studies showing a small stimulatory effect of estrogen on IGF-I mRNA levels in 
neonatal rat-derived bone cells (Ernst etal.1989; Ernst et al., 1991a). Co-treatment of 
osteoblasts with PGE2 and 17(3-estradiol, however, results in a potent, dose-dependent 
suppression of IGF-I promoter activation that is ER dependent and estradiol isomer 
selective (McCarthy el al., 1997). Our results are consistent with in vivo studies in rats 
that reveal a rise in IGF-I levels in bone tissue post-0VX, an effect that is attenuated with 
systemic estrogen treatment (Sato el al., 1993). 
As with 17|3-estradiol, in these studies OH-tamoxifen alone has no effect on IGF-I 
promoter activity over a range of concentrations from 0.1 nM to 1 pM Also similar to 
estrogen, OH-tamoxifen is capable of suppressing PGE2 induced IGF-I activity, although 
it is significantly less potent. Only a partial estrogen agonist, tamoxifen has been 
reported in other studies to be less potent than estrogen Work by Galien et al. (1996) 
demonstrating estradiol repression of TNFa-induced IL-6 secretion also investigated the 
effects of OH-tamoxifen. As with results reported here, tamoxifen displayed only 
intermediate agonism (approximately 50% the potency of estrogen) in cultures of human 
osteosarcoma cells, despite displaying full antagonism in breast cancer cell cultures 
(Pottratz et al., 1994). Interestingly, this reflects partial agonist and antagonist actions 
seen in vivo in bone and breast tissue. Similarly, while both tamoxifen and estrogen 
cause an increase in trabecular bone in OVX rats, estrogen was 25% more effective than 
a 50-fold higher dose of tamoxifen (Turner et al., 1988). In another study, the increase in 
cancellous bone apposition rate in the OVX rat was suppressed 63% by estrogen 
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Tamoxifen, though significantly decreasing the apposition rate, did so only by 18% (Kalu 
et al., 1991a). Likewise, tamoxifen was not as potent as estrogen at inhibiting radial 
growth in OVX rats, nor did tamoxifen increase uterine weight as much as estrogen 
(Moon et al., 1991). Both 17f3-estradiol and OH-tamoxifen increase intracellular cAMP 
in uterine cell cultures, but once again the response to a 100-fold higher dose of 
tamoxifen was less dramatic (Aronica et al., 1994). Therefore evidence derived from 
OVX rats and cell culture systems supports the conclusion that tamoxifen, while 
behaving as an estrogen agonist in certain tissues, is less potent. 
Nonetheless, comparing cell culture to in vivo results poses a degree of difficulty. 
Therapeutic serum levels of tamoxifen in patients and rats is reported at 5 x 10'7 M, while 
concentrations of 10"4 to lO^M may be necessary to achieve in vitro effects, and such 
high concentrations can even prove cytostatic to cells (Turner et al., 1988). This may be 
explained partially by the fact that compared to estrogen, OH-tamoxifen has been 
reported to have lower availability in serum-containing medium and more restricted entry 
into cells (Aronica et al., 1994). Also, while many cell culture experiments have used 4- 
OH-tamoxifen, and was the form used in experiments for this study, many animal studies 
have employed systemic administration of tamoxifen. Although 4-OH-tamoxifen is a 
100- to 1000-fold more potent active metabolite of tamoxifen that is found in the serum 
of breast cancer patients, it is unclear whether this particular metabolite is the locally 
active form in bone. Tamoxifen is metabolized to numerous different compounds, and 
many of these have different estrogenic or antiestrogenic potential (Jordan & Murphy, 
1990). Certain forms may be concentrated in different tissues, and this may contribute to 
the tissue specific actions of tamoxifen. Thus, while the effects of OH-tamoxifen on 
reducing PGE2 stimulated IGF-I expression are consistent with in vivo studies, 
conclusions regarding its absolute potency can only be surmised 
Next, we sought to compare the mechanism of tamoxifen action to what we 
understand of the actions of estrogen and its influences on IGF-I expression. IGF-I 
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transcription is stimulated by agents such as PGE2 and PTH that increase intracellular 
cAMP. PGE2 stimulated expression of IGF-I is PKA dependent (McCarthy et al., 1995). 
Although the IGF-I promoter 1 contains a single, near consensus CRE and several 
potential binding sites for transcription factor AP-2, deletion of these regions does not 
block PGE2 induced cAMP stimulation of IGF-I promoter activity. Rather, the DNA 
sequence HS3D, located in a the 5’-untranslated region (UTR) of exon 1, is integral to 
PGE2 stimulation of IGF-I although it has no nucleotide sequence similarity to the 
consensus CRE (Thomas et al., 1996). The active factors are not present in the 
cytoplasm, and cycloheximide treatment does not interfere with the PGE2 induced rise in 
IGF-I mRNA. PKA is thought to activate nuclear pre-existing DNA binding proteins, 
which may then interact with specific nucleotides within the HS3D DNA sequence 
(Thomas et al., 1996). 
Recent data generated in our laboratory indicate that 17(3-estradiol does not 
inhibit PGE2 induced IGF-I expression by interfering with cAMP production, but rather 
may alter protein-protein interactions between transcription factors (McCarthy et a!., 
1997). cAMP levels rise with PGE2 treatment, and are unaffected by co-treatment or pre¬ 
treatment with estrogen. A gel-mobility shift assay of 32P-labeled oligonucleotide 
containing HS3D using nuclear extracts of cells revealed reduced intensity of the PGE2 
induced gel shift band when extracts were prepared with cultures co-treated with PGE2 
and estrogen. The IGF-I promoter 1 contains no ERE, and no modification was seen in 
the gel mobility shift pattern of the HS3D probe with nuclear extracts from estrogen 
treated cultures. This suggests that estrogen may act via an ERE-independent 
mechanism, possibly affecting protein-protein interactions between the ligand activated 
ER and the cAMP activated transcription factor(s) involved in IGF-I expression (Fig. 8). 
Such an interaction may limit the binding ability of the activated transcription factor(s) 
for the HS3D element. 
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Tamoxifen may work in a similar manner. Using the gel-mobility shift assay with 
,2P-labeled HS3D probe and nuclear extracts from tamoxifen treated cells, no detectable 
change in gel-shift pattern was observed, making it unlikely that tamoxifen alone can 
significantly elevate cAMP levels in these cultures. Therefore, tamoxifen, like estrogen, 
does not alter DNA binding, in agreement with results from cell cultures revealing no 
change in activity of the IGF-I promoter by estrogen or tamoxifen treatment. However, 
treatment of cells with tamoxifen plus PGE2 and electrophoresis of nuclear extracts with 
the 32P-labeled HS3D probe demonstrates that tamoxifen decreases the intensity of the 
PGE2 inducible gel-shift bands compared to extracts from cells treated with PGE2 alone. 
Just as tamoxifen was not as potent as estrogen in cell cultures, inhibition detected with 
the gel-shift assay was not as marked. 
Interestingly, the actions of estrogen and tamoxifen may be enhanced in the 
presence of elevated cAMP levels, perhaps explaining in part why estrogen and 
tamoxifen have detectable effects only in the presence of PGE2. Protein kinase activators 
have been shown to have a synergistic effect on estrogen-dependent ER-mediated 
transcription functioning through a consensus ERE (Cho & Katzenellenbogen, 1993). 
Observations in our laboratory illustrate that estrogen dependent stimulation of the ERE 
was elevated in the presence of PGE2, suggesting additional and alternate interactions 
between estrogen action and cAMP from those observed for the IGF-I promoter. 
Furthermore, preliminary results from our experiments indicate that tamoxifen 
stimulation of the (ERE)2PRL-Luc was likewise enhanced when given in combination 
with PGE2. 
Although data suggest that tamoxifen acts via a similar ER-dependent mechanism 
as estrogen, estrogen and tamoxifen differentially activate transcription through the ERE, 
depending on the cellular context. While estrogen strongly activates the classical ERE, 
tamoxifen does so only weakly, indeed if at all In our studies, OH-tamoxifen 
consistently and significantly stimulated the ERE to a very low degree at the highest 
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concentration tested (lpM), thereby confirming that this concentration of tamoxifen is 
likely not cytotoxic. Other studies similarly report no or very weak tamoxifen activation 
of the ERE, ranging from 3% to 30% of estrogen induction, depending upon species and 
cell type (Webb et al., 1995). In in vitro studies, tamoxifen bound to ER recognizes an 
ERE specifically (Berry et al, 1990), indicating that tamoxifen does allow ER binding to 
ERE, unlike the pure antiestrogen ICI which inhibits ER dimerization and prevents its 
interaction with the ERE (Webb etal, 1995). 
The weak interaction of tamoxifen with the ERE may be due to differential 
activation of the ER (Rochefort & Borgna, 1981; Tzukerman et al., 1994). The 
molecular structure of the ER consists of discrete domains which can function 
independently; two of the most highly conserved regions are the DNA binding domain 
(DBD) (region C) and the hormone binding domain (HBD) (region E). The ER exhibits 
hormone-induced conformational changes that appear to be compound specific, as the 
antiestrogen ICI induced a different conformation of the HBD than estrogen (Beekman et 
al, 1993). Two independent transcriptional activation functions, TAF-1 and TAF-2, of 
the ER have been characterized (Lees etal, 1989; Danielian etal, 1992). The activity of 
TAF-1, located in the amino-terminus, is constitutive, while TAF-2, in the carboxyl- 
terminal within the HBD, is hormone inducible (Kumar et al, 1987). The activity of 
TAF-1 and TAF-2 depend upon cell specificity and target gene promoter context (Tasset 
et al, 1990). It has been reported that OH-tamoxifen, in contrast to estradiol, cannot 
induce TAF-2 activity, and thus the partial agonist characteristics of tamoxifen may stem 
from selective, and consequently limited, TAF-1 activity (Berry etal, 1990; Tzukerman 
etal, 1994). 
Alternately, the partial estrogenic properties of tamoxifen have also been 
proposed to arise via activation of an ERE-independent pathway. The ER can stimulate 
transcription from a promoter that contains an AP-1 site, the binding site for transcription 
factors Jun and Fos (Gaub et al, 1990; Umayahara et al, 1994). Since this function does 
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not depend on an intact ER DBD, this pathway may act via protein-protein interactions 
(Webb et al., 1995). Additional support for a non-genomic, ERE-independent pathway 
was provided by in vitro experiments demonstrating that protein kinase activators 
synergistically enhance estrogen-dependent ER-mediated transcriptional activation 
without altering the DNA binding properties of the ER (Cho & Katzenellenbogen, 1993). 
Estrogen repression of the IL-6 promoter was also shown to be ERE-independent, 
mediated instead by interactions with the DBD of the ER and DNA binding and 
dimerization domains for the transcription factors NF-kB and C/EBP involved in 
regulation of IL-6 (Pottratz eta/., 1994; Stein & Yang, 1995). 
Data from our laboratory likewise support the ERE-independent pathway of 
estrogen action within the IGF-I promoter 1 in osteoblasts. Furthermore, tamoxifen, like 
estrogen, suppressed PGE2 induced IGF-I promoter activation, and this effect was limited 
to a DNA sequence that lacked both AP-1 and ERE binding sites. We demonstrate for 
the first time the effects of tamoxifen in osteoblast cultures on IGF-I activity both alone 
and in conjunction with PGE2. Co-treatment of cells with PGE2 and tamoxifen or 
estrogen results in decreased binding to HS3D, the 5’-UTR region of IGF-I PI containing 
an atypical CRE crucial for PGE2 stimulation. Further studies are ongoing in our 
laboratory to characterize the nature of potential inhibitory protein-protein interactions. 
The discovery of alternate pathways of estrogen action in various tissues other 
than the classical ERE helps to elucidate the seemingly contradictory actions of partial 
estrogen antagonists such as tamoxifen. As our knowledge of these different mechanisms 
increases, the possibilities for future therapeutic interventions grow Postmenopausal 
hormone replacement therapy could be targeted to bone and cardiovascular systems to 
maximize the beneficial effects of estrogen on these tissues while minimizing actions on 
uterine tissue, thus obviating the need to combine an estrogen with progesterone 
Additionally, in premenopausal or postmenopausal patients with increased risk of breast 
cancer, antiestrogen therapy specific to breast tissue would have application as a 
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chemoprophylactic agent while maintaining bone mineral density in the skeleton 
Estrogen analogues specific to uterine and ovarian tissue could have potential use as 
fertility agents. Undoubtedly, the future ability to target estrogenic or antiestrogenic 
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Figure 8. Proposed model for the interaction of 17(3-estradiol (and 
4-OH-tamoxifen) with cAMP mediators of IGF-I promoter 
activation. Protein kinase A activation results in enhanced IGF-I 
promoter transcription. While estrogen (or tamoxifen) alone do not 
affect IGF-I promoter activity, these steroid hormones suppress PKA 
activation possibly through protein-protein interactions between ligand 
bound estrogen receptor and the cAMP activated transcription factor(s), 
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